Do people become addicted to Wegovy, Ozempic, and GLP1 medications?

It has become one of the most-searched questions about the entire GLP1 era. People type it into their phones late at night, often after their second or third month on the medication, when the appetite has gone clear and a small, uncomfortable thought has arrived in its place. Am I going to need this forever. Am I getting hooked on this. Is this addiction. The question is not loud or hysterical; it is private, and it is appearing in a great many private conversations at once.

The cultural conversation has been less careful. Magazines have used the word addiction loosely, social media has used it dramatically, and pharmaceutical companies, predictably, have tried not to use it at all. Somewhere underneath all of that, millions of users are steadily trying to work out a much more honest version of the question — not whether the medication is addictive in the way the headlines suggest, but whether something more subtle, more human, and harder to name is happening to their relationship with food, control, and their own body.

This article is an attempt to take the question seriously. What addiction actually means in a clinical sense, what users are really describing, what the early science says, and why the answer turns out to be both steadier and more interesting than the public conversation has so far allowed.

The quick answer

Why this question is everywhere right now

A few things have arrived at the same time, and the addiction conversation is what falls out of the overlap. The first is scale. More than ten million people are now estimated to be taking a GLP1 medication for weight, with the real number probably higher once compounded and off-label use is included. The second is duration — many of those users are now eighteen months or two years into their journey, far enough in to have started asking the long-term questions the original prescriptions did not always answer. The third is the visibility of the conversation. Social media has made what used to be a private question about a medication into a public, searchable, share-able one.

The fourth, and most underdiscussed, is cultural. Society has, for complicated reasons, never quite settled into a comfortable view of medications that treat obesity. There is no equivalent moral conversation about whether people on long-term blood pressure medication are addicted to their pills. The question is reserved, almost exclusively, for treatments that involve weight, food, and the body — a category in which moral judgement has always run ahead of medical understanding.

Why so many people fear stopping

The fear of stopping a GLP1 medication is not, in the main, the fear of physical withdrawal — most users have read enough to know that is not what the drug does. The fear is something more layered, and it tends to have several components.

The first is the fear of weight regain. Users have, in most cases, worked hard, paid significantly, and watched their bodies change in ways that have been emotionally meaningful. The early trial data, which has been frank about regain after stopping, is widely known. Users do the obvious mental arithmetic and arrive at a very rational discomfort with the idea of taking the last injection.

The second is the fear of food noise returning. For a large share of users, the disappearance of the constant mental pull toward food has been the most surprising and emotionally important part of the journey. Many describe it as the first time in their adult lives they have experienced an ordinary, clear relationship with eating. The thought of that clear ending is, understandably, harder to face than the thought of the weight returning.

The third, and the most overlooked, is the fear of losing the version of themselves that emerged during the journey. The user who has spent twelve months on the medication is often not the same person who started. Confidence, identity, body image, social and intimate life — all of these have frequently shifted. The fear of stopping is partly a fear of going backwards through that change.

What happens when people stop taking GLP1 medications? →

What addiction actually means, in a clinical sense

It is worth slowing down on this, because the word has become so culturally loaded that it has almost lost its medical meaning. In clinical practice, addiction is not simply a strong attachment to something. It is a defined pattern that includes a number of specific features: compulsive use of a substance despite clear harm, tolerance, a withdrawal syndrome when use stops, neurochemical changes in the brain's reward system, loss of control over the substance, and a continued pursuit of it even when it is damaging the user's life. The diagnostic criteria for substance use disorder, used by clinicians worldwide, are quite specific, and they are not satisfied by the experience of finding a medication helpful and being reluctant to stop.

GLP1 medications, by every available measure, do not meet these criteria. They do not act on the brain's dopaminergic reward circuitry in the way that addictive substances do. They do not produce a high — in fact, if anything, they tend to slightly dampen the reward signal around food, which is the opposite of how addictive substances behave. Stopping them does not produce a withdrawal syndrome of the kind seen with opioids, benzodiazepines, alcohol, or nicotine. Users do not develop cravings for the medication itself; they develop, at most, anxiety about the loss of its effects.

This distinction matters, because it changes the question. The honest question is not whether users are becoming addicted to the molecule. The honest question is whether something else, more subtle and entirely human, is happening — and whether the word addiction, used loosely, is obscuring more than it reveals.

Psychological attachment, named honestly

What many users are describing, when they reach for the word addiction, is closer to what clinicians would call psychological attachment or therapeutic dependence. It is the experience of having found a medication that genuinely improves the quality of daily life, and of becoming reluctant to imagine life without it. This is neither rare nor pathological. It is the same relationship a person with anxiety often develops with the medication that finally let them sleep, or that a person with chronic pain develops with the treatment that gave them their evenings back. It is not addiction. It is gratitude with a fear attached.

Where the experience around GLP1 medications is genuinely novel is in the breadth of what they seem to be steadily resolving. Users are not only losing weight. They are reporting steadier relationships with alcohol, less compulsive snacking, fewer intrusive thoughts about food, more energy, more confidence, often improved mood, and a general sense of an internal noise level dropping by several decibels. When a medication is doing that much, the attachment that forms around it is, in some sense, exactly proportional to the relief it has brought.

Calling that attachment addiction is both inaccurate and, in a more subtle way, unkind. It frames a very human response to a useful treatment as a failing of the user, when in fact it is a reasonable reaction to a meaningful improvement in daily life.

What users actually describe online

If you spend a few hours reading the major GLP1 communities — Reddit threads, TikTok comment sections, Facebook groups for specific medications — a clearer picture emerges than the one most magazine headlines offer. The word addiction does come up, often, but it is almost always used in a self-reflective, slightly worried tone rather than a clinical one. Users write things like, this feels almost too good, or, I'm scared of how much I don't want to stop, or, is it bad that I want to be on this forever. The conversation is overwhelmingly one of attachment rather than compulsion.

Underneath the surface conversation are a few recurring themes. The first is the experience of finally feeling normal around food, often for the first time in the user's adult life — and the clear grief that comes with realising how much of life had been spent in a different relationship with eating. The second is the fear, often more emotional than logical, of going back to that previous self. The third is a kind of moral self-questioning that is almost entirely absent in conversations about other long-term medications: users wondering whether they should be able to do this without help, whether wanting to stay on the medication is a kind of cheating, whether they are doing something wrong by feeling so much better.

None of this is the texture of addiction. It is the texture of a person who has had a long, difficult relationship with food and weight and has been handed a tool that meaningfully eases it, and who is trying to make sense of what that means for the rest of their life.

The emotional side: confidence, identity, and relief

Much of what looks, from the outside, like attachment to the medication is, on closer inspection, attachment to the version of life the medication has made possible. Confidence is the most consistently described change. Energy, presence, social ease, the willingness to be seen — these tend to arrive in the same six-to-twelve-month window as the weight loss, and they are often what users are steadily reluctant to lose.

There is also a deep emotional relief around food that is harder to describe. Users frequently say that the medication has freed up a kind of mental bandwidth they did not realise they had been spending. The constant background calculation — what to eat, when to eat, how to not eat too much, the next snack, the next meal, the calorie maths, the guilt, the negotiation — has, for many, gone clear. That clear is, for some people, the most meaningful thing the medication has given them. The thought of losing it is correspondingly difficult.

Calling that emotional relief addiction misreads it. What the user is attached to is not the drug; it is the absence of a noise they have been living with for years.

Why food thoughts drop on GLP1 →

The long-term question, asked honestly

One of the genuinely new conversations of the past two years is whether GLP1 medications are simply going to be long-term treatments for many users, in the same conceptual category as medications for blood pressure or cholesterol. Clinicians who treat obesity have, in their professional guidance, largely already arrived at this view. They describe obesity as a chronic, relapsing condition, and GLP1 medications as ongoing treatment for it. The public conversation, shaped by older assumptions about weight loss as a finite event, has been slower to catch up.

What is becoming clearer is that a meaningful share of users will likely stay on these medications for years, often at lower maintenance doses, with the goal of holding rather than continuing to lose. Others will cycle on and off. A smaller group will use the medication for a defined period and discontinue with active maintenance support. None of these paths is failure, and none of them is addiction.

The arrival of GLP1 pills, expected to broaden access significantly later in the decade, will probably make long-term low-dose use considerably more common than it currently is. The honest framing is that what the public still thinks of as a temporary intervention is, for many users, going to look more like a long-term tool.

The next generation of GLP1 pills →

Is dependence always a bad thing?

It is worth pausing on this question, because the assumption underneath much of the addiction conversation is that needing a medication long-term is a problem in itself. That assumption is rarely applied to other chronic conditions. Nobody asks a person with type two diabetes whether they have become addicted to their metformin. Nobody asks a person with hypothyroidism whether they should worry about lifelong dependence on their thyroid hormone. The framing is reserved, almost entirely, for weight-related medication, and the reasons for that are cultural rather than medical.

Obesity has, for decades, been treated by mainstream culture as a moral failing rather than a chronic medical condition. The arrival of effective medication has begun to shift that view, but the older framing has not disappeared. The addiction conversation, looked at honestly, is partly a continuation of an older argument about whether obesity is the kind of condition that deserves long-term medical treatment at all — an argument that, on the medical side, was settled some time ago.

When a chronic medication is improving the quality of someone's daily life, the question of whether they will need it for a long time is not the most important question. The most important question is whether the medication is working, whether the benefits outweigh the costs and risks, and whether the user is supported in using it well. None of those questions has anything to do with addiction.

What the science actually suggests

The honest summary of what is currently known is fairly clean. GLP1 medications do not produce the neurochemical signatures of addictive substances. They do not act on the brain's reward circuitry in the way drugs of abuse do. Stopping them does not produce a withdrawal syndrome. Users do not develop tolerance in the addiction sense — although dose escalation is part of the protocol for clinical reasons, that is a different phenomenon from the tolerance seen in addictive substances.

There is, intriguingly, an emerging body of research suggesting GLP1 medications may actually reduce certain addictive behaviours rather than create new ones. Early observational data from users has noted reductions in alcohol consumption, nicotine cravings, and even gambling behaviour in some patients. Small trials are now examining semaglutide and tirzepatide as potential treatments for alcohol use disorder. The mechanism is thought to involve the medication's reducing effect on the brain's reward signalling around hedonic — pleasure-driven — consumption. Whether this translates into clinically meaningful addiction treatment is still being studied, but the direction of the evidence is the opposite of what the addiction headlines would suggest.

What the science does not yet have a complete answer for is the longer psychological story — what years of living with a lower relationship to appetite does to a person's identity, eating patterns, and emotional life, and what happens to those things when the medication is removed. That is a real and important set of questions, and they deserve careful research. They are not, however, questions about addiction. They are questions about how powerful and personal a medication can be, and how to think clearly about long-term use of something that genuinely changes lives.

What clinicians are actually saying

The most experienced obesity-medicine clinicians have, on the whole, been steady about this conversation. They tend to make a few points consistently. First, that obesity is a chronic, relapsing condition and that effective treatment for it is, by definition, often long-term. Second, that the fear users feel around stopping is rational and worth taking seriously, and is not the same as addiction. Third, that the most useful thing for users is not to debate whether they are addicted, but to plan honestly for the long-term shape of their treatment — including the possibility of staying on, of stepping down, or of stopping with structured support, depending on what fits their life.

Where clinicians do raise concerns, they tend to be about the broader system rather than the medication itself. The fear that some users may be prescribed GLP1 medications without adequate psychological support around eating, body image, and identity. The fear that the cultural conversation, by stigmatising long-term use, may push some patients to stop prematurely. The fear, in the opposite direction, that some users may use the medication to avoid examining the underlying patterns it is steadily easing. None of these are addiction concerns. They are care concerns, and they deserve serious attention.

What seems to help users who are struggling with this question

Users who appear to navigate the addiction question well, in the sense of arriving at a steady and honest view of their own use, tend to share a few things. They tend to talk about it openly — with a clinician, a partner, a clinician, or a trusted community — rather than holding it as a private anxiety. They tend to have built habits around the medication that would survive its absence, even if imperfectly. They tend to have read the early data honestly, without either dismissing the risk of regain or catastrophising it. And they tend to have given themselves permission, in advance, for several different long-term shapes the journey could take.

• Reading the actual clinical definition of addiction, rather than relying on the cultural one.
• Distinguishing between attachment to the medication itself and attachment to the version of life it has made possible.
• Naming the fear of stopping directly, with a clinician or clinician, rather than letting it run in the background.
• Building habits — protein, sleep, walking, strength training, structured meals — that exist alongside the medication, not because of it.
• Reframing long-term use, where it fits, as a reasonable response to a chronic condition rather than a failure of willpower.
• Giving themselves permission for the journey to take a different shape than the one they originally planned.

The bigger picture

It is probably worth saying that the addiction question is, in many ways, a stand-in for a much larger cultural conversation that is only beginning. Obesity medicine has, in the past three years, become genuinely effective for the first time in history. Society has not yet worked out how to feel about that. The old assumptions — that weight is fundamentally a matter of personal choice, that medication for it is somehow cheating, that long-term use of such medication is suspicious in a way long-term use of other chronic medications is not — are being slowly revised in real time, in millions of private conversations.

Some of the discomfort that surfaces as the addiction question is, in honest terms, the discomfort of that revision. It is hard to admit that a medication can do what willpower could not, hard to make peace with the idea that the body's relationship with food may not have been entirely under conscious control all along, hard to sit with the unfairness of a tool arriving thirty years too late for some people. The addiction framing is, in part, a way of putting that discomfort somewhere it can be named.

The more useful framing is also the simpler one. These medications are powerful, they are improving the daily lives of millions of people, they are not addictive in any clinical sense, and they may be long-term treatments for a meaningful share of users. The fear of needing them forever is human and worth taking seriously. It is not the same thing as being addicted to them.

A final reflection

The conversation around GLP1 medications and addiction is probably going to continue for years. It will get louder before it gets clearer. New trials will arrive. The pills will broaden access. The cultural conversation will eventually mature into something more honest than the one currently being conducted on magazine covers.

Underneath the noise, the question most users are actually asking is much lower, and much more interesting. Not whether they are addicted, but what it means to have found a medication that genuinely changes their relationship with one of the most fundamental things a body does. How to think about long-term use of something that has eased a noise they had been living with for years. How to be honest about the parts of the change they would not want to give up. How to plan, with care, for the next chapter of a journey that may not have a tidy ending.

The most useful answer, in the end, is probably the steadiest one. The medication is a tool. The user's relationship with their own body is the longer story. The two will continue to negotiate with each other for a long time, and the conversation will be richer if the loudest word in it stops being addiction.

Track your journey with GLP1 Journal →